FGEN vs WAT · rev $29.6M vs P/E 32, rev $3.17B
FibroGen Inc (FGEN) versus Waters Corporation (WAT) — a side-by-side from cached financials, not a winner call.
FibroGen Inc (FGEN) is a biotechnology company listed on NASDAQ.
Waters Corporation (WAT) is a diagnostics & research company listed on US.
Latest reported FGEN revenue for 2024-12-31 was $29.6M. Net income was -$47.6M. Revenue was down 36.7% from 2023-12-31 to 2024-12-31. FGEN currently screens at market cap $39.3M.
Latest reported WAT revenue for 2025-12-31 was $3.17B. Net income was $642.6M. WAT currently screens at market cap $20.84B and trailing P/E 31.8.
FGEN currently screens at market cap $39.3M. WAT currently screens at market cap $20.84B and trailing P/E 31.8.
Not investment advice. Open the FGEN and WAT stock pages for the full models.
Not investment advice.